ArticleHereditas2025
The potential role of biomarkers CD28 and PF4 in the pathogenesis of idiopathic pulmonary fibrosis and their impact on the prognosis: an immune microenvironment analysis.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThis study aims to identify and investigate biomarkers associated with mitochondrial-related genes (MRGs) and programmed cell death-related genes (PCDRGs) that concurrently influence the progression of idiopathic pulmonary fibrosis (IPF) and to explore the underlying biological mechanisms involved.
methodsThe GSE28042 and GSE27957 datasets, comprising 1,136 MRGs and 1,548 PCDRGs, were utilized in this study. Differentially expressed genes (DEGs) between the IPF and control groups were initially identified through differential expression analysis. Subsequently, key module genes closely associated with IPF samples were selected using Weighted Gene Co-expression Network Analysis (WGCNA). Intersection genes 1 and 2 were then identified by overlapping DEGs with key module genes, MRGs, and PCDRGs. Candidate genes were further selected through Spearman correlation analysis involving intersection genes 1 and 2. Additionally, biomarkers were identified, and a risk model was developed using Cox regression analysis, proportional hazards (PH) assumption testing, and machine learning methods. Patients with IPF were stratified into high- and low-risk cohorts. Finally, functional enrichment analysis, immune infiltration analysis, regulatory network construction, and reverse transcription quantitative PCR (RT-qPCR) were conducted separately to validate the findings.
resultsCD28 and PF4 were identified as biomarkers, and a risk model was established. The distinct risk cohorts exhibited differences in pathways related to hemostasis, prion diseases, and other biological processes. A significant positive correlation with was observed between CD28 and native CD4 T cells, while PF4 showed a negative correlation with activated NK cells. Based on these two biomarkers, 30 miRNAs and 532 lncRNAs were predicted, resulting in the construction of a lncRNA-miRNA-biomarker network. Additionally, 11 chemicals associated with these biomarkers were identified. RT-qPCR analysis further confirmed that expression levels of CD28 and PF4 were significantly reduced in IPF samples (P < 0.05).
conclusionThe results of this study suggested that the biomarkers CD28 and PF4 might play a potential role in the pathogenesis of IPF and might have an impact on the prognosis of the disease. These findings might offer valuable insights for future treatment strategies and prognostic evaluation for patients with IPF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.